Amenorrhea

Premature ovarian insufficiency (POI) occurs when ovarian function declines in women before age 40, significantly affecting health and quality of life. This research aims to better understand the causes, progression, and health impacts of POI, as well as evaluate hormone replacement therapy (HRT) options. The study will create a hospital-based, multi-center case-control and prospective cohort to gather comprehensive data on POI's natural course and effects. The study includes several groups: women diagnosed with POI, control women with regular menstrual cycles, those scheduled for ovarian surgery, and those undergoing oophorectomy. Participants provide biological samples, lifestyle and health information, and undergo long-term follow-up assessments. Data collection spans multiple health factors including reproductive hormones, bone density, psychological well-being, and metabolic markers. Participants will be monitored at regular intervals up to 36 months with tests such as bone density scans, hormone level checks, blood glucose and insulin measurements, and psychological assessments for anxiety and depression. The study also tracks symptoms related to low estrogen and sexual health. Safety and health outcomes are observed through blood counts, liver and kidney function tests, and ultrasound exams. This comprehensive approach aims to deepen understanding and support improved care for women with POI.

This research aims to evaluate the effects of royal jelly major proteins (MRJPs) delivered as rose tablet candies on ovarian function and endometrial receptivity in women aged 20 to 45 with normal menstrual cycles. The study will explore how MRJPs influence female reproductive health, focusing on their role in improving fertility factors such as hormone levels, ovarian reserve, and the uterine lining's ability to support embryo implantation. It also seeks to determine the safety and potential clinical value of MRJPs for reproductive medicine. Participants will be randomly assigned to one of two groups: one receiving oral MRJPs candy containing 70% MRJPs freeze-dried powder, and the other receiving a placebo candy mainly composed of whey protein powder. Both groups will take one tablet twice daily for one menstrual cycle. The MRJPs candy uses patented technologies to ensure quality and stability of the active ingredients. The placebo group allows comparison to evaluate the specific effects of MRJPs. Throughout the trial, researchers will monitor hormone levels, including anti-Müllerian hormone, and assess endometrial receptivity from enrollment through the one-month treatment period. Various tests and measurements will be conducted to track ovarian function and hormonal changes. The study is conducted with ethical oversight and scientific rigor to protect participants and ensure reliable results, with total participation lasting about one menstrual cycle plus screening and follow-up.

This observational study aims to understand how force feedback instruments are useful during surgeries performed with the da Vinci 5 robotic system. It focuses on procedures such as inguinal and ventral hernia repairs, colorectal, thoracic, gynecologic surgeries, and partial nephrectomy. The study is designed to gather information on how these instruments perform during robotic-assisted surgery. Participants will undergo multi-port robotic-assisted surgery using the da Vinci 5 system equipped with force feedback instruments, which provide tactile sensations. The study observes surgeries planned as primary procedures with these instruments, without altering the treatment. There is no experimental drug or placebo involved, as this is an observational study conducted after the devices have been marketed. During the study, researchers will measure the force applied to tissues by the force feedback instruments during surgery and evaluate how useful these instruments are during specific steps of the procedure before patient discharge. Participants will be followed up as per the study protocol to ensure data quality. The total participation time varies depending on the surgical procedure and follow-up schedule.

Researchers are evaluating whether acupuncture, specifically the Dragon's protocol, can help reduce chronic pelvic pain in women aged 21 to 65. This study focuses on non-endometriosis pelvic pain and includes women both with and without a history of sexual assault. The Dragon's protocol acupuncture aims to address both physical pain and emotional trauma by combining external and internal acupuncture treatments to reprocess traumatic memories and potentially calm the nervous system. Participants will first undergo 4 weeks of standard pain care such as physical therapy, psychotherapy, or usual medical management. Then, the same women will receive acupuncture treatments once weekly for 4 weeks using the Dragon's protocol. The acupuncture involves placing needles on both the back (external dragons) and front (internal dragons) of the body during each session, aiming to balance traumatic memories and pain responses. Throughout the study, participants will complete pain assessments using the Defense and Veterans Pain Rating Scale (DVPRS) and the Female Genitourinary Pain Index (GUPI) at multiple visits from week 0 to week 11. Women with a history of sexual trauma will also complete the PTSD Checklist for DSM-5 (PCL-5) to evaluate changes in PTSD symptoms. Visits include screening, baseline, weekly acupuncture sessions, and follow-ups, some of which may be virtual. Researchers will monitor pain levels and quality of life to understand the impact of the acupuncture treatment.

Researchers are studying how Antimüllerian Hormone (AMH) levels can predict the risk of future infertility in girls aged 3 to 14 who are undergoing cancer treatment or treatment for benign diseases. The goal is to identify young patients who may have a reduced ovarian reserve after treatment and could benefit from special follow-up or fertility preservation. The study includes children at high, moderate/low, or no risk of ovarian damage from chemotherapy or pelvic irradiation. The study observes AMH and other hormone levels before and after treatment, with no interventions applied. Participants are grouped by their risk level: high risk patients receiving conditioning therapy or pelvic irradiation; moderate/low risk patients treated with chemotherapy regimens for various cancers; and a control group with no risk, consisting of patients with benign diseases or cancers not requiring gonadotoxic treatment. Assessments occur at diagnosis, treatment end, and during follow-up visits scheduled yearly for three years, then every two years until age 18. Participants will have their ovarian reserve evaluated through hormone tests including AMH, FSH, estradiol, testosterone, and LH, alongside menstrual cycle tracking and pubertal development assessed annually using Tanner staging and bone age X-rays. The primary outcome is the AMH marker measured regularly up to 18 years old. Secondary outcomes include premature ovarian failure and ovarian reserve changes. The study also monitors oncological outcomes as per standard care, with a total follow-up duration extending to 18 years old.

Researchers are collecting Real-World Data (RWD) to study the ongoing safety and effectiveness of the anovo Surgical System during transvaginal gynecological laparoscopic surgeries. They are also evaluating how the anovo Skills Development Pathway affects surgeon behavior and performance, focusing on the learning curve and procedure outcomes across surgeons with different experience levels. The study aims to minimize bias by including a broad patient population. The study involves surgeons using the anovo Surgical System, an endoscopic instrument control device designed to assist in controlling instrument arms during single site, natural orifice laparoscopic-assisted transvaginal benign gynecological surgeries. The study collects data on surgery times and adverse device events, while tracking surgeon competency development through the Skills Development Pathway. Participants will be patients undergoing gynecological surgery with the anovo Surgical System. Researchers will collect data on conversion rates to other surgical approaches and monitor for unanticipated adverse device effects up to 8 weeks post-surgery. Patients will also complete post-operative questionnaires to provide additional information. This observational registry study provides ongoing safety and performance data to understand device use in real-world settings.

Researchers are conducting an observational study to improve understanding of the menstrual cycle and various gynecologic health conditions such as polycystic ovary syndrome (PCOS), infertility, and breast cancer. This study focuses on reproductive health and menstrual patterns in women and aims to gather long-term data to describe these aspects epidemiologically. The study is hosted on the Apple Research app, which participants can use to find, enroll in, and take part in this research. It collects data related to menstrual cycle patterns and the prevalence of gynecologic health conditions over a period of up to 10 years. Participants will engage through the app, providing information about their menstrual cycles and health conditions. The study tracks menstrual cycle patterns and collects epidemiologic data over time, also determining the prevalence of related health issues. This observational approach allows long-term monitoring without administering treatments. The study is expected to continue through November 2029.

Researchers are investigating the use of autologous adipose stromal vascular fraction (SVF) to improve pregnancy outcomes in women with premature ovarian insufficiency (POI). This single-center, prospective, randomized controlled trial aims to evaluate the safety and effectiveness of SVF treatment compared to conventional reproductive care in infertile patients with POI. The study will enroll 260 women diagnosed with POI and is sponsored by Rui Yang. Participants will be randomly assigned to one of two groups. The experimental group will undergo lower abdominal liposuction to collect fat tissue, from which SVF will be prepared and then injected into both ovaries under ultrasound guidance. The control group will receive standard assisted reproductive treatments without SVF. Both groups will receive conventional in vitro fertilization (IVF) procedures and related reproductive care. Treatment and follow-up will span approximately two years, including six visits and three phone follow-ups. During the study, researchers will monitor various outcomes such as the cumulative clinical pregnancy rate within six months, hormone levels, follicle counts, ovarian volume, menstrual status, pregnancy outcomes, and offspring health over two years. Safety will also be assessed by tracking any adverse reactions. Participants will undergo tests, hormone measurements, ultrasounds, and questionnaires to evaluate these outcomes and monitor their health throughout the study period.

Female fertility can be affected by several factors including ovarian function, fallopian tube health, the uterine environment, and mental state, with the ovaries and endometrium playing key roles. Common reproductive diseases impacting fertility include ovarian dysfunction, poor ovarian response, intrauterine adhesion, recurrent implantation failure, and thin endometrium. These conditions currently lack effective treatments, and platelet-rich plasma (PRP) shows promise, prompting further research into its effects and mechanisms. This study evaluates the use of platelet-rich plasma injections delivered via transvaginal or laparoscopic methods for ovarian diseases such as premature ovarian insufficiency and poor ovarian response. For uterine diseases including intrauterine adhesion, thin endometrium, and repeated implantation failure, PRP is administered through intrauterine perfusion or injections under the endometrium. The study focuses on monitoring the safety of PRP treatment up to three months post-enrollment. Participants are female patients aged 18 to 50 years diagnosed with one of the specified reproductive diseases. Their progress will be tracked through assessments of adverse and serious adverse events from enrollment through the three-month treatment period. Researchers will evaluate the safety of PRP injections and collect data to better understand its potential therapeutic effects in reproductive medicine.

This research aims to compare the thickness of the endometrial lining in adolescent and young adult females on estrogen replacement therapy using two types of progesterone treatments: daily oral micronized progesterone and the etonogestrel implant. The study focuses on patients aged 12 to 25 years with specific diagnoses requiring estrogen therapy, addressing gaps in knowledge about endometrial protection and bleeding patterns in this group. Participants will choose between two progesterone therapies: oral micronized progesterone taken daily at 100mg or the etonogestrel implant placed in a clinic. The study will last six months, during which participants will continue their estrogen therapy and start their selected progesterone treatment. Two pelvic ultrasounds will be performed, one at the start and one after six months of progesterone use, to measure changes in endometrial thickness. Throughout the study, participants will complete surveys about bleeding patterns, side effects, satisfaction, and adherence to their progesterone treatment. The study team will track medication use through pill counts or photos for those on oral progesterone. All ultrasound and survey data will be securely stored and analyzed to assess the mean change in endometrial thickness and other patient-reported outcomes over six months.